Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InhibOx and Cambridge Crystallographic Data Centre (CCDC) have entered into a collaboration to create a drug discovery service offering with the help of the companies' commercial drug discovery experience and proprietary technologies developed by the Oxford and Cambridge bodies.
Subscribe to our email newsletter
The combined drug discovery service is expected to provide access to new capabilities for accelerating drug discovery and improve productivity to the pharmaceutical, biotech and governmental research organisations.
InhibOx and CCDC said that the new drug discovery service consists of full-spectrum computer-aided drug discovery (CADD) from receptor site modeling, through lead identification, lead optimisation and ADME property prediction to formulation modeling.
Under the collaboration InhibOx and the CCDC are expected to jointly commercialise and support the new service and share operating expenses and revenues. Sales and service operations for the new, combined service are based out of Oxford and Cambridge, UK, and Princeton.
Additionally, InhibOx and CCDC are expected to jointly develop new approaches to bring scientific breakthroughs and productivity benefits to all aspects of computer-aided drug discovery.
Colin Groom, executive director of CCDC, said: “We have been asked more and more frequently by our users whether we can bring to bear our in-house drug discovery experience to address their research challenges. The alliance with InhibOx gives us the breadth of technology and a focused team to meet this demand.”
Paul Davie, CEO of InhibOx, said: “The drive to outsourcing by pharmaceutical enterprises, and the resulting emergence of a new wave of biotechs and CRO’s, has created a sudden need for computer-aided drug discovery services. CADD cannot be delivered effectively by companies with just point solutions or a few off-the-shelf tools.”